



Tenascin-C

Heart Failure / Cancer / Auto-Immune

- Research Use Only -

Assay Kits

【Sample Type】 H: Human M: Mouse R: Rat

Product No.	Sample Type	Product Name	Measurement Range	Measuring samples				
				Serum	Heparin-Plasma	EDTA-Plasma	Urine	Cell Culture Supernatant
27751	H	Human Tenascin-C Large (FNIII-C) Assay Kit - IBL	0.38 ~ 24 ng/mL	○	○*1	○*2	/	○
27767	H/M/R	Tenascin-C Large (FNIII-B) Assay Kit - IBL	0.20 ~ 12.5 ng/mL	○	/	○*3	/	○*4

*1: more than x5 dilution is recommended.

*2: Plasma samples collected with EDTA, Sodium citrate or NaF showed somewhat lower value.

*3: x400 - x1600 dilution is recommended.

*4: cross-reacts with FCS in medium.

Antibodies

【Sample Type】 H: Human

Product No.	Sample Type	Product Name	Application	Size	Small size
10337	H	Anti-Human Tenascin-C (EGF Like Domain) (4F10TT) Mouse IgG MoAb	WB (1ug/mL), IHC (5ug/mL) * 1	100μg	10μg
10335	H	Anti-Human Tenascin-C (Domain B) (4C8MS) Mouse IgG MoAb	WB (5ug/mL), IHC (5ug/mL) *2	100μg	10μg

*1: Can be applied to formalin fixed paraffin embeded tissue with trypsin pre-treatment.


*2: Microwave pre-treatment is necessary.

Structure of Tenascin-C

Tenascin-C is an extracellular matrix (ECM) glycoprotein that is composed of 210-400 kDa subunits consisting of four domains.

One subunit has a TA domain at the N-terminal end, then an epidermal growth factor-like sequence domain (EGF-like domain), a fibronectin type III (FN III) repeat domain, and a fibrinogen-like domain at the C-terminal end. There is an alternatively spliced domain in the FN III domain, and it generates some types of variants of Tenascin-C.

The subunits form a trimer by twisting at the N-terminal coiled domain and form a hexamer by a disulfide bond, in tissue.



Distributed by

Tenascin-C

27751 Human Tenascin-C Large (FNIII-C) Assay Kit – IBL
27767 Tenascin-C Large (FNIII-B) Assay Kit - IBL

Two assay kits for measuring Tenascin-C are available. Each assay kit specifically detects FN III-B or FN III-C domain in FN III repeat and measures Tenascin-C high molecular weight variant (called as “Large”) including the subunit in which FN III-B or FN III-C domain respectively.


While low molecular weight variants of Tenascin-C are present in normal tissue, it is said that high molecular variants of Tenascin-C is expressed in various diseased tissue including cancers.

10337 Anti-Human Tenascin-C (EGF Like Domain) (4F10TT) Mouse IgG MoAb

This monoclonal antibody specifically recognizes EGF-like domain of Tenascin-C and it detects in all Tenascin-C isoforms and cross-react with mouse, rat, chicken and rabbit.

10335 Anti-Human Tenascin-C (Domain B) (4C8MS) Mouse IgG MoAb

This monoclonal antibody specifically recognizes domain B on FN III repeat of Tenascin-C and is useful for the study of organogenesis, tumor, cell injury caused by various types of stress, wound healing, regeneration and fibrosis. It cross-reacts with mouse and rat.



These are results of IHC of human breast cancer tissue (References No.6).

References

1. Terasaki F, Okamoto H, Onishi K, Sato A, Shimomura H, Tsukada B, Imanaka-Yoshida K, Hiroe M, Yoshida T, Kitaura Y, Kitabatake A; Study Group for Intractable Diseases by a Grant from the Ministry of Health, Labor and Welfare of Japan. Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. *Circ J*. 2007 Mar;71(3):327-30.
2. Takeda A, Otani Y, Iseki H, Takeuchi H, Aikawa K, Tabuchi S, Shinozuka N, Saeki T, Okazaki Y, Koyama I. Clinical significance of large tenascin-C spliced variant as a potential biomarker for colorectal cancer. *World J Surg*. 2007 Feb;31(2):388-94.
3. Sato A, Aonuma K, Imanaka-Yoshida K, Yoshida T, Isobe M, Kawase D, Kinoshita N, Yazaki Y, Hiroe M. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. *J Am Coll Cardiol*. 2006 Jun 6;47(11):2319-25.
4. Sato A, Aonuma K, Imanaka-Yoshida K, Yoshida T, Isobe M, Kawase D, Kinoshita N, Yazaki Y, Hiroe M. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. *J Am Coll Cardiol*. 2006 Jun 6; 47 (11):2319-25.
5. Tanaka H, El-Karef A, Kaito M, Kinoshita N, Fujita N, Horiike S, Watanabe S, Yoshida T, Adachi Y. Circulating level of large splice variants of tenascin-C is a marker of piecemeal necrosis activity in patients with chronic hepatitis C. *Liver Int*. 2006 Apr; 26 (3):311-8.
6. Hasegawa M, Sudo A, Nagakura T, Hirata H, Kinoshita N, Yoshida T, Uchida A. Tenascin-C levels in pseudosynovial fluid of loose hip prostheses. *Scand J Rheumatol*. 2005 Nov-Dec; 34 (6):464-8.
7. Morimoto S, Imanaka-Yoshida K, Hiramitsu S, Kato S, Ohtsuki M, Uemura A, Kato Y, Nishikawa T, Toyozaki T, Hishida H, Yoshida T, Hiroe M. Diagnostic utility of tenascin-C for evaluation of the activity of human acute myocarditis. *J Pathol*. 2005 Mar; 205 (4):460-7.
8. Hasegawa M, Hirata H, Sudo A, Kato K, Kawase D, Kinoshita N, Yoshida T, Uchida A. Tenascin-C concentration in synovial fluid correlates with radiographic progression of knee osteoarthritis. *J Rheumatol*. 2004 Oct; 31 (10):2021-6.
9. Imanaka-Yoshida K, Hiroe M, Yoshida T. Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling. *Histol Histopathol*. 2004 Apr; 19 (2):517-25.
10. Tsunoda T, Inada H, Kalembeiyi I, Imanaka-Yoshida K, Sakakibara M, Okada R, Katsuta K, Sakakura T, Majima Y, Yoshida T. Involvement of large tenascin-C splice variants in breast cancer progression. *Am J Pathol*. 2003 Jun;162 (6):1857-67.
11. Sato M, Toyozaki T, Odaka K, Uehara T, Arano Y, Hasegawa H, Yoshida K, Imanaka-Yoshida K, Yoshida T, Hiroe M, Tadokoro H, Irie T, Tanada S, Komuro I. Detection of experimental autoimmune myocarditis in rats by ¹¹¹In monoclonal antibody specific for tenascin-C. *Circulation*. 2002 Sep 10;106(11):1397-402.
12. Imanaka-Yoshida K, Hiroe M, Yasutomi Y, Toyozaki T, Tsuchiya T, Noda N, Maki T, Nishikawa T, Sakakura T, Yoshida T. Tenascin-C is a useful marker for disease activity in myocarditis. *J Pathol*. 2002 Jul;197(3):388-94.
13. Imanaka-Yoshida K, Hiroe M, Nishikawa T, Ishiyama S, Shimojo T, Ohta Y, Sakakura T, Yoshida T. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. *Lab Invest*. 2001 Jul;81(7):1015-24.
14. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. *Dev Dyn*. 2000 Jun;218(2):235-59.
15. Hanamura N, Yoshida T, Matsumoto E, Kawarada Y, Sakakura T. Expression of fibronectin and tenascin-C mRNA by myofibroblasts, vascular cells and epithelial cells in human colon adenomas and carcinomas. *Int J Cancer*. 1997 Sep 26;73(1):10-5
16. Yoshida T, Matsumoto E, Hanamura N, Kalembeiyi I, Katsuta K, Ishihara A, Sakakura T. Co-expression of tenascin and fibronectin in epithelial and stromal cells of benign lesions and ductal carcinomas in the human breast. *J Pathol*. 1997 Aug;182(4):421-8.